



## PRESS RELEASE

# ***Normax to invest in first Vax Factory for mRNA vaccine manufacturing in Dublin, Ireland***

*Normax is building a path for rapid growth of its global headquarters in Dublin, Ireland. With €300 million capital commitment from a cornerstone investor for research, development and manufacturing of mRNA vaccines*

**DUBLIN, Ireland. 19 November 2022** - Normax plans to invest €30,000,000 in its first Vax Factory in Dublin after recently securing a €300 million pre-IPO capital commitment to help drive down the cost of vaccines, save more lives and support long-term sustainable pandemic preparedness. Aiming to boost its presence and the development of affordable pan-Coronavirus mRNA vaccine boosters, the expansion of the business comes amid a busy year for Normax who plan to use the €300 million capital commitment to scale up mRNA Vaccine R&D for COVID, Tuberculosis (TB), HIV, Malaria and the inevitable outbreak of "Disease-X".

Normax mission is to become a global market leader in mRNA Vaccine R&D and distributed manufacturing. Ireland is a favoured location for corporate headquarters and global business services. Dublin is the [fourth most attractive European city to investors](#) and is a world leader in key innovative sectors, including healthcare, technology, and research. Dublin rose in attractiveness: 17% this year compared with just 6% in 2021, [according to EY European Investment Monitor 2022](#).

Until recently, the UK was considered a prime destination for many businesses looking to gain a foothold in the European market. However, Brexit has thrown these plans into uncertain waters and many organisations have had to reconsider their strategic growth plans. Ireland is one of Europe's top 10 locations for Foreign Direct Investment (FDI). Normax corporate headquarters in Ireland enables freedom and flexibility to innovate and grow in the global mRNA vaccine and therapeutics market.

The pandemic is not over. Despite the end of lockdowns in many countries and more than [15 million COVID deaths](#) so far, new variants are continuously emerging. During the pandemic supply and demand issues of vaccines arose with just [22.7%](#) of people in low-income countries being able to receive only one dose of the vaccine. In the event of another crisis, global mRNA vaccine customers require reliable shipping and delivery. With a major international airport, Dublin is located on the East Coast of Ireland and is a crucial port with ease of access to the United Kingdom, The EU, Africa, and the United States.

Currently, leading COVID mRNA vaccine producers charge governments \$8-\$35 per dose. Normax plans to charge about \$4 per dose for large scale delivery of safe and effective regulatory approved mRNA vaccines on advance purchase agreements. At Normax, the mission is to deliver 100 novel mRNA Vaccines and 100 Vax Factories in up to fifty countries.

*"Our plans to build our first Vax Factory in Dublin is a milestone in our ongoing journey of innovation and our growing footprint in Ireland. Dublin has the potential for a means of no end. We believe Dublin can enable Normax with a platform to deliver research and development of mRNA vaccines for COVID, TB, HIV, and Malaria whilst investing and deploying modular mRNA Vaccine Factories, in up to one hundred locations. In the event of another public health emergency, we are also committed to delivering future mRNA vaccines in 100 days, to help ensure that COVID-19 is the last pandemic we will all suffer through. Pathogens are inevitable, but diseases are not,"* says Peter A. Jensen, CEO and Chairman of Normax.



As well as research and development of the Universal Coronavirus mRNA Vaccine (UCV-mRNA), Normax is developing mRNA vaccine R&D and manufacturing strategies for TB and HIV, with the goal to end transmission of these deadly infectious diseases by 2050.

About 2.4 million people die every year from TB and HIV/AIDS, with a combined estimated global healthcare cost of more than \$120 billion per year – a future potential monthly healthcare cost savings of \$10 billion dollars and 200,000 lives saved.

With closure of €300 million pre-IPO capital investment commitment, Normax now plans an initial public offering (IPO) with a listing on the [SIX Swiss Exchange](#) with digital Normax subsidiary company listings on [SIX Digital Exchange \(SDX\)](#)

**ENDS**

### **About Normax**

Normax Biomed Limited is incorporated in Ireland. Not an offer to invest. See Red Herring Disclosure.

**Outbreaks are inevitable. Pandemics are not.** Normax is on a mission to be a strategic partner in the global ecosystem for transformative research, development, and manufacture of safe and effective mRNA vaccines for global public health and pandemic preparedness and prevention.

**Vax Factory by Normax.** With a focus on partnership and open science, Normax is and investing in the future of mRNA Vaccines through shared R&D, scientific expertise, agility, and innovation, for the COVID-19 pandemic, infectious disease and long-term sustained pandemic preparedness and prevention. Our vision is to create a Freedom to Operate (FTO) ecosystem for mRNA Vaccines, where research and development can co-exist with an established Good Manufacturing Process (GMP) factory network at large-scale, small-scale and micro-scale.

**How mRNA Vaccines Work.** mRNA vaccine technology is a transformative new sector of the biopharmaceutical industry which has revolutionised vaccine development through increased speed, safety and cost-effective development leading to the first approved vaccines for the COVID-19 pandemic. It is estimated that over seven billion mRNA vaccines for COVID will be shipped by the end of 2022. mRNA technology allows researchers to fast-track the initial stages of vaccine research and development and thereby to produce safe and effective mRNA vaccines faster and more efficiently.

### **The story of Normax in 2 minutes**

- [The Mission of Normax mRNA Vaccine R&D and Manufacturing Business](#) (1:00)
- [Normax mRNA Vaccines. Pathogens are inevitable. Diseases are not.](#) (1:00)

More company information can be found at [normaxbiomed.com](http://normaxbiomed.com)

### **Media contact:**

Berkeley Communications

+44 118 909 0909

[normax@berkeleypr.com](mailto:normax@berkeleypr.com)

### **Investor Contact**

Normax Biomed Limited

[normaxbiomed.com/contact/](http://normaxbiomed.com/contact/)



## **Disclaimer**

THIS MEDIA RELEASE SERVES INFORMATIONAL PURPOSES AND CONSTITUTES NEITHER AN OFFER TO SELL NOR A SOLICITATION OR AN ADVERTISEMENT TO BUY ANY SHARES OF NORMAX BIOMED LTD. IN ANY JURISDICTION. This Media Release does not constitute a prospectus for the purposes of the listing of shares of Normax Biomed Ltd. This media release and the information contained therein are not being issued in the United States of America, Australia, Canada, Japan, or the European Economic Area and must not be distributed within or to such countries or via publications with a general circulation in such countries. This Media Release is directed only at and may only be communicated to persons: (a) if in an EEA member state, who are qualified investors within the meaning of Article 2(e) of the Prospectus Regulation ("Qualified Investors"); (b) in the United Kingdom who (i) have professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the "FPO") or fall within the definition of "high net worth companies, unincorporated associations etc" in Article 49(2)(a) to (d) of the FPO and (iii) are "qualified investors" as defined in Article 2(e) of the Prospectus Regulation as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018; and (c) otherwise to whom it may otherwise lawfully be communicated. This Media Release contains forward-looking statements such as projections, forecasts, and estimates. Such forward-looking statements are subject to certain risks and uncertainties which may cause actual results, performance, or events to differ materially from those anticipated in this media release. The forward-looking statements contained in this media release are based on the views and assumptions of Normax Biomed Ltd. as of this date and Normax Biomed Ltd. does not assume any obligation to update or revise this media release.